Status:
TERMINATED
Image Guided Therapy in the Treatment of Gliomas
Lead Sponsor:
NYU Langone Health
Conditions:
Glioma
Eligibility:
All Genders
7+ years
Phase:
NA
Brief Summary
RATIONALE: New imaging techniques using magnetic resonance imaging give better tumor definition, thus may lead to better tumor targeting and avoid damaging critical parts of normal brain. PURPOSE: Th...
Detailed Description
PRIMARY OBJECTIVES: I. To correlate the imaging findings with pathological grade following surgery in patients with newly diagnosed intra-cranial gliomas. SECONDARY OBJECTIVES: I. To determine the ...
Eligibility Criteria
Inclusion
- Histologically confirmed, newly diagnosed intracranial glioma
- A diagnostic contrast enhanced CT/MRI demonstrating the lesion prior to registration
- Karnofsky performance status \>= 60
- Ability to undergo MR imaging with the use of Gadolinium dye
- Patient must sign a study specific informed consent form; if the patient's mental status precludes his/her giving informed consent, written informed consent may be given by the patient's legal representative
Exclusion
- Inability to obtain histological proof of glioma
- Allergy to Gadolinium contrast
- Any condition including metallic implants or cardiac pace makers that make the candidate ineligible for MR imaging
- Any medical condition including renal or cardiac insufficiency that make the candidate a high risk for gadolinium contrast administration
- Karnofsky performance status of =\< 50
- Prior history of radiation therapy to the brain
- Pregnancy
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01263821
Start Date
August 1 2009
End Date
April 1 2014
Last Update
August 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Cancer Institute
New York, New York, United States, 10016